Stock Events

Stock Events

CohBar 

$0.4100
21
-$0.04-8.89%Thursday 20:11

Statistics

Day High
0.41
Day Low
0.41
52W High
1.01
52W Low
0.0011
Volume
172
Avg. Volume
3,044
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

Nov 22Expected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Q3 2024
-1.49
-1.24
-1
-0.75
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
0Revenue
-12.18MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Senseonics
SENS
Mkt Cap522.4M
Senseonics Holdings focuses on diabetes management solutions, competing indirectly with CohBar's metabolic disease targets.
Conmed
CNMD
Mkt Cap1.39B
ConMed Corporation, while more broadly focused on medical devices, competes in the space of treatments for conditions that CohBar's therapies may also address.
Lineage Cell Therapeutics
LCTX
Mkt Cap235.28M
Lineage Cell Therapeutics works on regenerative therapies for diseases of aging, which overlaps with CohBar's therapeutic development goals.
Geron
GERN
Mkt Cap770.97M
Geron Corporation's focus on telomerase inhibitors for cancer and aging diseases places it in competition with CohBar's approach to aging and metabolic diseases.
Sarepta Therapeutics
SRPT
Mkt Cap1.85B
Sarepta Therapeutics, known for its work in genetic modulation and rare diseases, competes in the broader market for innovative treatments in areas that could intersect with CohBar's interests.
vTv Therapeutics
VTVT
Mkt Cap120.87M
vTv Therapeutics focuses on clinical-stage drug development for diabetes and Alzheimer's, competing in the metabolic disease and aging space relevant to CohBar.

About

CohBar, Inc., a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease. Its lead clinical candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial derived peptide, which is in Phase Ib stage of a Phase Ia/Ib clinical trial for the treatment of NASH and obesity. The company's preclinical programs include CB5138 analogs for fibrotic diseases; and CB5064 analogs for COVID-19 associated ARDS. CohBar, Inc. was incorporated in 2007 and is headquartered in Menlo Park, California.
Show More
CEO
Dr. Pinchas Cohen Dean, M.D., Ph.D.
Employees
9
Country
United States
ISIN
US19249J1097

Listings

0 Comments

Share your thoughts

FAQs

What is CohBar stock price today?▼
The current price of CWBR is $0.41 USD — it has decreased by -8.89% in the past 24 hours. Watch CohBar stock price performance more closely on the chart.
What is CohBar stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTCMTKS exchange CohBar stocks are traded under the ticker CWBR.
What is CohBar revenue for the last year?▼
CohBar revenue for the last year amounts to 0 USD.
What is CohBar net income for the last year?▼
CWBR net income for the last year is -12.18M USD.
How many employees does CohBar have?▼
As of October 6, 2026, the company has 9 employees.
In which sector is CohBar located?▼
CohBar operates in the Health & Wellness sector.
When did CohBar complete a stock split?▼
The last stock split for CohBar was on September 23, 2022 with a ratio of 1:30.
Where is CohBar headquartered?▼
CohBar is headquartered in Menlo Park, United States.